Efavirenz-induced decrease in plasma amprenavir levels in human immunodeficiency virus-infected patients and correction by ritonavir.
Duval
X
X
Le Moing
V
V
Longuet
C
C
Leport
C
C
Vildé
J L
JL
Lamotte
C
C
Peytavin
G
G
Farinotti
R
R
D000480:Alkynes; D019380:Anti-HIV Agents / Q000097:blood* / Q000494:pharmacology / Q000627:therapeutic use; D001189:Aryl Hydrocarbon Hydroxylases; D048588:Benzoxazines; D002219:Carbamates; D003521:Cyclopropanes; D051544:Cytochrome P-450 CYP3A; D065607:Cytochrome P-450 Enzyme Inhibitors; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005663:Furans; D015658:HIV Infections / Q000097:blood* / Q000188:drug therapy; D006801:Humans; D010078:Oxazines / Q000494:pharmacology* / Q000627:therapeutic use; D010089:Oxidoreductases, N-Demethylating / Q000037:antagonists & inhibitors; D019438:Ritonavir / Q000494:pharmacology* / Q000627:therapeutic use; D013449:Sulfonamides / Q000097:blood* / Q000627:therapeutic use
D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D002219:Carbamates; D003521:Cyclopropanes; D065607:Cytochrome P-450 Enzyme Inhibitors; D005663:Furans; D010078:Oxazines; D013449:Sulfonamides; C095108:amprenavir; D001189:Aryl Hydrocarbon Hydroxylases; D051544:Cytochrome P-450 CYP3A; D010089:Oxidoreductases, N-Demethylating; C098320:efavirenz; D019438:Ritonavir